PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN DWP16001, A NOVEL SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR, AND METFORMIN IN HEALTHY SUBJECTS.

被引：0
作者：
Chung, W. [1 ]
Lee, S. [1 ]
Na, J. [1 ]
Lee, S. [1 ]
Lee, S. [1 ]
Cho, J. [1 ]
Jang, I. [1 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-039
引用
收藏
页码：S39 / S40
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects
    Stocker, Sophie L.
    Williams, Kenneth M.
    McLachlan, Andrew J.
    Graham, Garry G.
    Day, Richard O.
    [J]. CLINICAL PHARMACOKINETICS, 2008, 47 (02) : 111 - 118
  • [32] Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects
    Sophie L. Stocker
    Kenneth M. Williams
    Andrew J. McLachlan
    Garry G. Graham
    Richard O. Day
    [J]. Clinical Pharmacokinetics, 2008, 47 : 111 - 118
  • [33] A PHARMACOKINETIC INTERACTION ASSESSMENT BETWEEN A NOVEL CYCLOPHILIN INHIBITOR ALISPORIVIR (ALV) AND A MACROLIDE ANTIBIOTIC AZITHROMYCIN (AZI) IN HEALTHY SUBJECTS.
    Ke, J.
    Barve, A.
    Kovacs, S.
    Dabovic, K.
    Praestgaard, J.
    Zhang, J.
    Stein, D.
    Sunkara, G.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S116 - S116
  • [34] ADDITIVE PHARMACODYNAMIC EFFECT WITHOUT PHARMACOKINETIC INTERACTION BETWEEN GEMIGLIPTIN, A NOVEL DPP-IV INHIBITOR AND METFORMIN IN HEALTHY VOLUNTEERS
    Shin, D.
    Lee, S.
    Lim, K.
    Jang, I.
    Shin, S.
    Ahn, J.
    Kim, J.
    Yu, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S108 - S108
  • [35] PHARMACOKINETIC INTERACTION BETWEEN RALOXIFENE AND CHOLECALCIFEROL IN HEALTHY KOREAN MALE SUBJECTS.
    Kang, W.
    Seong, S.
    Ohk, B.
    Kim, H-J.
    Yoon, Y-R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S39 - S39
  • [36] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS BETWEEN EVOGLIPTIN AND PIOGLITAZONE AFTER ORAL ADMINISTRATION IN HEALTHY SUBJECTS.
    Jeon, I.
    Park, K.
    Hwang, I.
    Yoon, S.
    Lee, H.
    Yu, K-S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S38 - S38
  • [37] ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN PRADIGASTAT AND EFAVIRENZ OR REPAGLINIDE IN HEALTHY SUBJECTS.
    Kulmatycki, K. M.
    Meyers, D.
    Danis, K.
    Neelakantham, S.
    Su, Z.
    Majumdar, T.
    Sam, R.
    Sunkara, G.
    Chen, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S49
  • [38] LACK OF A PHARMACOKINETIC INTERACTION BETWEEN DIMEBON (LATREPIRDINE) AND DIGOXIN IN HEALTHY SUBJECTS.
    Qiu, R.
    Plowchalk, D.
    Byon, W.
    Terra, S.
    Corrigan, B.
    Mordenti, J.
    Fang, J.
    Fullerton, T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S91 - S91
  • [39] Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects.
    Liu, P
    Foster, G
    Labadie, R
    Gutierrez, MJ
    Sharma, A
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P40 - P40
  • [40] Pharmacokinetic and pharmacodynamic aspects of the interaction between clazosentan and nimodipine in healthy subjects
    van Giersbergen, P. L. M.
    Dingemanse, J.
    [J]. CEREBRAL VASOSPASM: NEW STRATEGIES IN RESEARCH AND TREATMENT, 2008, 104 : 127 - 130
12345